Table 2 MYCN RNA in situ hybridization expression and clinicopathologic factors in patients (n = 69) with neuroblastoma
Variables | Case number | MYCN RNA in situ hybridization low expression | MYCN RNA in situ hybridization high expression | P value |
|---|---|---|---|---|
Age at diagnosis (months) | ||||
≦18 months | 32 | 23 (72%) | 9 (28%) | 0.017* |
>18 months | 37 | 16 (43%) | 21 (57%) | |
Gender | ||||
Male | 41 | 24 (59%) | 17 (41%) | 0.683 |
Female | 28 | 15 (54%) | 13 (46%) | |
International Neuroblastoma Staging System stage | ||||
1, 2, 4s | 23 | 19 (83%) | 4 (17%) | 0.002* |
3, 4 | 46 | 20 (43%) | 26 (57%) | |
Primary tumor site | ||||
Adrenal | 53 | 27 (51%) | 26 (49%) | 0.089 |
Extraadrenal | 16 | 12 (75%) | 4 (25%) | |
International Neuroblastoma Pathology Classification histology | ||||
Favorable | 33 | 27 (82%) | 6 (18%) | <0.001* |
Unfavorable | 36 | 12 (33%) | 24 (67%) | |
MYCN | ||||
Amplified | 17 | 3 (18%) | 14 (82%) | <0.001* |
Non-amplified | 52 | 36 (69%) | 16 (31%) | |
Children’s Oncology Group risk group | ||||
Nonhigh risk | 25 | 21 (84%) | 4 (16%) | 0.001* |
High risk | 44 | 18 (41%) | 26 (59%) | |
